640290-67-1
640290-67-1
Chemical Structure
Nelonemdaz
Synonym(s): Salfaprodil free base; Neu2000
- CAS No.: 640290-67-1
- Formula:C15H8F7NO3
- Molecular Weight:383.22
IUPAC Name: 2-hydroxy-5-((2,3,5,6-tetrafluoro-4-(trifluoromethyl)benzyl)amino)benzoic acid
InChIKey: HABROHXUHNHQMY-UHFFFAOYSA-N
SMILES: OC(C1=C(O)C=CC(NCC2=C(C(F)=C(C(F)(F)F)C(F)=C2F)F)=C1)=O
Biological Activity: Nelonemdaz (Salfaprodil free base) is an NR2B-selective and uncompetitive antagonist of N-methyl-D-aspartate (NMDA). Nelonemdaz is also a free radical scavenger. Nelonemdaz has excellent neuroprotection against NMDA- and free radical-induced cell death[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Nelonemdaz | 99.87% | Nelonemdaz (Salfaprodil free base) is an NR2B-selective and uncompetitive antagonist of N-methyl-D-aspartate (NMDA). Nelonemdaz is also a free radical scavenger. Nelonemdaz has excellent neuroprotection against NMDA- and free radical-induced cell death. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Nelonemdaz (Standard) | ≥98% | Nelonemdaz (Standard) is the analytical standard of Nelonemdaz (HY-106408). This product is intended for research and analytical applications. Nelonemdaz (Salfaprodil free base) is an NR2B-selective and uncompetitive antagonist of N-methyl-D-aspartate (NMDA). Nelonemdaz is also a free radical scavenger. Nelonemdaz has excellent neuroprotection against NMDA- and free radical-induced cell death. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Gwag BJ, et al. Marked prevention of ischemic brain injury by Neu2000, an NMDA antagonist and antioxidant derived from aspirin and sulfasalazine. J Cereb Blood Flow Metab. 2007 Jun;27(6):1142-51. [Content Brief]
- [2]. Sung IC, et, al. Neu2000, an NR2B-selective, Moderate NMDA Receptor Antagonist and Potent Spin Trapping Molecule for Stroke. Drug News Perspect. 2010 Nov; 23(9): 549-56. [Content Brief]
